Ruconest (C1 esterase inhibitor, recombinant) is a brand-name drug prescribed to treat acute episodes of hereditary angioedema in adults and some children. It’s given as an intravenous (IV) injection ...

Ruconest can cause certain side effects, some of which are more common than others. These side effects may be temporary, lasting a few days to weeks. However, if the side effects last longer than that ...

Uncrowned is a new destination for all things MMA, boxing, wrestling, and more, featuring Ariel Helwani. SAN DIEGO, CA and LEIDEN, THE NETHERLANDS--(Marketwire - Nov 7, 2012) - Statistically ...

Pharming Group (NASDAQ:PHAR) executives outlined commercial performance, pipeline priorities, and regulatory updates during a presentation at Oppenheimer’s 36th Annual Healthcare Conference, highlight ...

Ruconest (C1 esterase inhibitor, recombinant) can cause side effects that range from mild to serious. More common side effects include headache and nausea. If side effects from Ruconest become ...

The US Food and Drug Administration (:FDA) recently accepted the Biologics License Application (:BLA) for Santarus, Inc. (SNTS) and partner, Pharming Group NV’s Ruconest. The companies are looking to ...

If you have heard of Ruconest, but you’re not sure what it is, then keep reading! Ruconest is an entirely manmade type of protein known as a C1 esterase inhibitor. C1 esterase inhibitor naturally ...

The FDA has rejected Pharming’s application to expand the licence of Ruconest, for a use as prophylaxis for patients with the serious rare disease hereditary angioedema (HAE). The FDA asked Pharming ...

Santarus and Pharming Group NV announced that the FDA has accepted for filing the Biologics License Application (BLA) for the investigational drug Ruconest (INN conestat alfa) 50 IU/kg for the ...

US regulators have turned down Pharming’s application to expand the approved uses of Ruconest to include prophylaxis in patients with hereditary angioedema (HAE). US regulators have turned down ...

SAN DIEGO, CA and LEIDEN, THE NETHERLANDS--(Marketwire - Nov 7, 2012) - Statistically significant results for primary endpoint of time to beginning of symptom relief Santarus, Inc. (NASDAQ: SNTS) and ...